FDA Inspection 1191458 — Zelalem (Nmi) Temesgen, M.D.
The FDA completed an inspection of Zelalem (Nmi) Temesgen, M.D. on Nov 4, 2022 in Rochester, MN. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 4, 2022
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Rochester, MN (United States)
Additional Details
Clinical Investigator (CI)